ACC 2024: Adding investigative lerodalcibep to cholesterol lowering treatment shows significant efficacy
By adding investigational lerodalcibep to their standard cholesterol-lowering treatment for a year, patients at high risk for a heart attack or stroke achieved a reduction of “bad” cholesterol… read more.
